Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators intend to show that DDAVP improves platelet activity from baseline to 60 minutes after treatment start.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University
• Collaborator: Northwestern Memorial Hospital
• Treatments: Deamino Arginine Vasopressin

Criteria

Inclusion Criteria:

• Spontaneous intracerebral hemorrhage as documented by head CT scan

• Documented regular aspirin use or VerifyNow-ASA result of ≤ 550 aspirin reaction units (ARU), indicating anti-platelet medication

Exclusion Criteria:

• International normalized ratio (INR) of ≥ 1.7 from coagulopathy or warfarin use

• History of von Willebrand disease

• Pregnancy

• Known hypersensitivity to DDAVP or desmopressin

• Active cardiovascular disease or unstable angina

• Hyponatremia or history of hyponatremia

• Current or historical deep venous thrombosis or pulmonary embolism